However, new microtubules stabilizing agents such as Davunetide and others [reviewed in (241)] exhibit promising disease-mitigating outcomes in animal models, with more manageable side-effects in clinical trials, and could therefore be the new frontier in the search for microtubules stabilizing strategies to ameliorate tau pathology in neurodegenerative diseases, including HD. This evidence concerns the gene MAPT and neurodegenerative disease.